Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
A brief guide to blue chip alternatives beyond BTC and ETH, highlighting characteristics that define blue chip status and potential rewards.
20,411 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Berkshire Hathaway's latest moves under Greg Abel show a shift toward stability with Apple while betting bigger on Al...
Inflation remains a stubborn backdrop, yet stocks are pushing higher. This article breaks down what’s driving the ral...
A sudden drop in Intuit's stock price can feel unsettling, but it may also open a window for patient investors. This ...
Investors over 50 are recalibrating away from crowded AI bets toward dividend growth and quality stocks that pay risi...
When Goldman Sachs raises its dividend as advisory and underwriting fees rebound, investors take notice. This article...
A prominent investor dumped $6.5 million of SentinelOne stock as the cybersecurity firm’s shares fell sharply. This a...
In March, following Buffett’s long-term approach, consider two stalwart names with durable moats and steady cash flow...
Circle announces a $222 million Arc token presale at a $3 billion FDV, drawing major investors as quarterly revenue g...
AI-driven optimism pushes the S&P 500 to an eighth consecutive week of gains, led by big tech earnings and AI infrast...
Markets can swing wildly, but your plan shouldn’t. This guide shows how to prepare for a stock market crash coming wi...
In a volatile market, a high-yield dividend stock demonstrates how investors can secure steady income. A $10,000 inve...